Trial Profile

A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mirzotamab clezutoclax (Primary) ; Docetaxel; Paclitaxel
Indications Advanced breast cancer; HER2 negative breast cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors AbbVie

Most Recent Events

20 Jan 2025 Planned End Date changed from 31 Dec 2024 to 1 Jun 2025.
20 Jan 2025 Planned primary completion date changed from 31 Dec 2024 to 1 Jun 2025.
01 May 2024 Planned End Date changed from 31 Mar 2024 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com